Shea Jacqueline Elizabeth 4

4 · INOVIO PHARMACEUTICALS, INC. · Filed Feb 27, 2026

AI-generated summary of this filing

Updated Feb 27, 2026

INOVIO (INO) CEO Jacqueline Shea Receives Restricted Shares

What Happened

Jacqueline Elizabeth Shea, CEO of INOVIO Pharmaceuticals (INO), had restricted stock units (RSUs) vest on February 26, 2026. A total of 47,033 RSUs vested (18,632 from a 2024 grant and 28,401 from a 2025 grant).
To cover tax withholding, the company withheld 21,714 shares (two withholding transactions of 8,057 and 13,657 shares) at $1.79 per share, totaling $38,868. After withholding, Shea received a net 25,319 shares.
This was a compensation/vesting event (not an open-market purchase or a discretionary sale).

Key Details

Transaction date: 2026-02-26; Form 4 filed 2026-02-27.
Vested shares: 47,033 (18,632 + 28,401). Shares withheld for taxes: 21,714 (8,057 + 13,657) at $1.79/share = $38,868.
Net shares delivered to insider: 25,319.
Transaction codes: M = exercise/conversion of derivative (conversion/settlement of RSUs); F = shares withheld to satisfy tax obligations.
Relevant footnotes: F1/F3 describe the original RSU grant schedules (2024 and 2025 grants). F2/F4 confirm the withheld-share transactions were to satisfy tax withholding on the vesting.
Shares owned after the transactions are not specified in this Form 4.

Context

This is a routine compensation event: RSUs vested and were settled with share withholding to cover taxes (a cashless settlement). No open-market sale or purchase beyond the withholding was reported.
Such filings typically reflect payroll/tax mechanics rather than an insider expressing a buy/sell opinion; purchases tend to be more informative about insider sentiment.

Form 4

Period: 2026-02-26

DirectorChief Executive Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-26+18,632→ 78,317 total
Tax Payment
Common Stock
[F2]
2026-02-26$1.79/sh−8,057$14,422→ 70,260 total
Exercise/Conversion
Common Stock
[F3]
2026-02-26+28,401→ 98,661 total
Tax Payment
Common Stock
[F4]
2026-02-26$1.79/sh−13,657$24,446→ 85,004 total
Exercise/Conversion
Restricted Stock Unit
[F1]
2026-02-26−18,632→ 18,631 total
→ Common Stock (18,632 underlying)
Exercise/Conversion
Restricted Stock Unit
[F3]
2026-02-26−28,401→ 56,800 total
→ Common Stock (28,401 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units granted on February 28, 2024 was as follows: 18,632 shares vested on February 26, 2025; 18,632 shares vested on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
[F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
[F3]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,201 restricted stock units granted on February 27, 2025 was as follows: 28,401 shares vested on February 26, 2026; 28,400 shares will vest on February 26, 2027; 28,400 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
[F4]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (3) herein.

Signature

/s/ Jacqueline E. Shea|2026-02-27

1 file